8 hours Ago By ABMN Staff
Marshall Wace LLP acquired a new stake in shares of Bicara Therapeutics Inc. ( NASDAQ:BCAX – Free Report ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 67,733 shares of the company’s stock, valued at approximately $1,180,000.
Marshall Wace LLP owned about 0.12% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business.
XTX Topco Ltd acquired a new stake in Bicara Therapeutics in the 4th quarter valued at approximately $476,000. Barclays PLC grew its holdings in Bicara Therapeutics by 201.1% in the 4th quarter.
Barclays PLC now owns 30,107 shares of the company’s stock valued at $524,000 after buying an additional 20,107 shares during the last quarter. Summit Investment Advisors Inc. acquired a new stake in Bicara Therapeutics in the 4th quarter valued at approximately $35,000.
Legal & General Group Plc acquired a new stake in Bicara Therapeutics in the 4th quarter valued at approximately $33,000. Finally, Invesco Ltd. acquired a new stake in Bicara Therapeutics in the 4th quarter valued at approximately $267,000.
Bicara Therapeutics Stock Performance Bicara Therapeutics stock opened at $14.88 on Wednesday. Bicara Therapeutics Inc.
has a one year low of $8.91 and a one year high of $28.09.
The business has a 50 day simple moving average of $12.84 and a 200 day simple moving average of $16.00.
Analyst Ratings Changes A number of analysts have issued reports on BCAX shares. Wells Fargo & Company started coverage on Bicara Therapeutics in a report on Thursday, April 17th. They issued an “underweight” rating and a $8.
00 target price on the stock. HC Wainwright reduced their price objective on Bicara Therapeutics from $45.00 to $44.
00 and set a “buy” rating for the company in a research report on Monday, April 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th.
Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Wedbush reiterated an “outperform” rating and issued a $31.
00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.
43. Check Out Our Latest Research Report on BCAX Bicara Therapeutics Company Profile ( Free Report ) Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
